Drug Profile
Research programme: epidermal growth factor receptor antagonists - Beta Pharma
Alternative Names: BPI-0403; BPI-4039Latest Information Update: 10 Nov 2016
Price :
$50
*
At a glance
- Originator Beta Pharma
- Class Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 09 Nov 2016 Discontinued - Preclinical for Pancreatic cancer in USA (unspecified route)
- 20 Nov 2014 Preclinical trials in Pancreatic cancer in USA (unspecified route)